Mayo Clinic Labs’ Dr. Bill Morice, who’s also board chair for the American Clinical Lab Association, describes the marketing challenge of demonstrating the value of the lab for healthcare.
Novartis unveils promising Fabhalta data for C3 glomerulopathy indication
Topline results from the Phase 3 trial, APPEAR-C3G, showed Fabhalta (iptacopan) met its primary endpoint in reducing protein in the urine in patients with C3G.
Celldex’s lead asset shows promise in 2 skin conditions
Celldex’s CSU, PN trials represent not only strong datasets but suggest barzolvolimab’s ‘pipeline-in-a-product potential’ in other mast cell-driven diseases.
Syndax’s acute leukemia drug succeeds in pivotal study
Supported by the hashtag #RaisingHealth, the campaign debuted with a 30-second ad titled “The Solvers,” which also ran on Northwell’s LinkedIn page, which has more than 178,000 followers.
Biogen’s Aduhelm marketing plan targeted communities of color — but clinical trials included very few non-white participants